• InterMune Inc., of Brisbane, Calif., reported fourth-quarter product revenue totaling $7.8 million, consisting of $2.7 million for sales of idiopathic pulmonary fibrosis drug Esbriet (pirfenidone) in Europe. The drug was launched in Germany last year and, as of Jan. 5, about 612 patients had been prescribed Esbriet.